Galapagos « Terug naar discussie overzicht

quote:

Investor68 schreef op 6 augustus 2015 13:25:

What a nonsense opinion from these so-called analysts, Jan de Kerpel en Joost van Beek, with their ridiculous "koersdoel" of 55 and 33 Euro per share for Galapagos. I wonder who made these people analysts? Are they really serious? Anyone with a modicum of intelligence and good business acumen and who truly understands the nature of Galapagos’ business and potential knows full well that Galapagos is worth far more than 33 or 55 Euro per share. Galapagos has proven that it can deliver good results. I suggest that these so-called analysts should look for another job. Investors in Galapagos are far more intelligent and sophisticated to allow themselves to be influenced by such miserable "koersdoel" from Jan de Kerpel and Joost van Beek

quote:

FC Barcelona schreef op 6 augustus 2015 13:36:

[...]

ik denk ; vrijdag ; stranddagje voor Gala personeel ! vanwege de team spirit en de mooie toekomst !

quote:

Investor68 schreef op 6 augustus 2015 14:21:

133 Euro sounds better for now. Though I expect Galapagos to trade up to 250 Euro within two years from now if the company is not taken over before then.

quote:

Chicken Little schreef op 6 augustus 2015 14:24:

[...]
why? Without any explanation such statements are as useful as ducks in a whorehouse.

quote:

_Giulietta_ schreef op 6 augustus 2015 14:30:

[...]

What is there to explain? Or were you just very much looking forward in using this comparison that you just seized whatever opportunity would land at your feet? :)

quote:

twinkletown schreef op 6 augustus 2015 10:59:

Ook belangrijk: Galapagos heeft voor 35,6 miljoen euro aan vorderingen openstaan bij de Franse overheid en bij de Belgische overheid voor 22,4 miljoen euro.

Vraag voor de forumleden: Ontvangt Galapagos ook nog de aanvullende betaling van 5 miljoen euro van het Amerikaanse Charles River labaratories? Dit bedrag zou worden overgemaakt als aan bepaalde omzetdoelstellingen van het eerste jaar -dus na de overname van Argenta en Biofocus per 1 april 2014- is voldaan.

quote:

Chicken Little schreef op 6 augustus 2015 14:41:

[...]
if someone throws out a prediction/expectation for a stock, I'd like to know the reasoning behind it. Otherwise, why share.

(And I really can't comprehend the second part of your comment)

quote:

_Giulietta_ schreef op 6 augustus 2015 15:02:

[...]

He oviously gave an expectation based on GLPG eventually launching filgotinib by themselves or reeling in the royalties from Abbvie. As we all are quite actively following GLPG you should very well know that such expectation - though uncertain, blue sky scenario, hence biotech - are very realistic.

The fact that you can't comprehend my general comment implies that you really didn't get Investor68 or as I attempted to imply just felt like responding to the first general comment available as it hardly made any sense at all.

As of your daily 2ish o' clock quite useless (thought must say often humoristic) comments we could say exactly the same, why share.